| scholarly article | Q13442814 |
| P50 | author | Jian Li | Q60621562 |
| P2093 | author name string | Roger L Nation | |
| Chun-Hong Tan | |||
| P2860 | cites work | Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin | Q45042604 |
| Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study | Q46571062 | ||
| Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). | Q54469153 | ||
| Multidrug-resistant Acinetobacter: a threat to the antibiotic era | Q63859735 | ||
| Old polymyxins are back: is resistance close? | Q80052849 | ||
| Using intrathecal colistin for multidrug resistant shunt infection | Q81178161 | ||
| Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin | Q95802946 | ||
| Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis | Q24802824 | ||
| Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria | Q34380004 | ||
| Overview of nosocomial infections caused by gram-negative bacilli | Q34444001 | ||
| Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections | Q34560321 | ||
| Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. | Q34680516 | ||
| Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii | Q35023321 | ||
| AcinetobacterOutbreaks, 1977–2000 | Q35119005 | ||
| Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians | Q35848861 | ||
| Antimicrobial resistance of Acinetobacter spp. in Europe | Q35859069 | ||
| Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections | Q36095874 | ||
| Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America | Q36382134 | ||
| Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. | Q39743535 | ||
| New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity | Q40618304 | ||
| Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin | Q42537114 | ||
| Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration | Q42653979 | ||
| A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. | Q43756818 | ||
| Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis | Q44636915 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colistin | Q418946 |
| pharmacodynamics | Q725307 | ||
| pharmacokinetics | Q323936 | ||
| Acinetobacter baumannii | Q3241189 | ||
| P304 | page(s) | 3413-3415 | |
| P577 | publication date | 2007-07-09 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model | |
| P478 | volume | 51 |
| Q34565772 | 'Old' antibiotics for emerging multidrug-resistant bacteria |
| Q42215035 | Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. |
| Q37014270 | Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii |
| Q33870110 | Antimicrobial drug use in food-producing animals and associated human health risks: what, and how strong, is the evidence? |
| Q37450764 | Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment |
| Q37147621 | Bugs versus drugs: addressing the pharmacist's challenge |
| Q37838126 | Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter? |
| Q39333751 | Clinical Pharmacokinetics and Pharmacodynamics of Colistin. |
| Q35364351 | Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula |
| Q40719307 | Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance |
| Q35008357 | Colistin and polymyxin B: peas in a pod, or chalk and cheese? |
| Q41912289 | Colistin heteroresistance in acinetobacter and its association with previous colistin therapy |
| Q33847509 | Colistin in the 21st century |
| Q34309451 | Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production |
| Q37996299 | Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies |
| Q33798324 | Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. |
| Q38048852 | Colistin: an update on the antibiotic of the 21st century |
| Q37949391 | Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists |
| Q37330689 | Current control and treatment of multidrug-resistant Acinetobacter baumannii infections |
| Q37669021 | Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. |
| Q35242165 | Dosing of colistin-back to basic PK/PD. |
| Q43069244 | Extensively drug-resistant Acinetobacter baumannii |
| Q37838117 | Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii |
| Q92302843 | History, Chemistry and Antibacterial Spectrum |
| Q92302869 | In vitro Pharmacodynamics and PK/PD in Animals |
| Q36308072 | In vitro evaluation of the potential for resistance development to ceragenin CSA-13. |
| Q42239726 | In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii |
| Q100634918 | In vivo bactericidal effect of colistin-linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia |
| Q36222127 | Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. |
| Q93000971 | Mechanisms and clinical relevance of bacterial heteroresistance |
| Q92302854 | Mechanisms of Polymyxin Resistance |
| Q37656243 | Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy |
| Q41027375 | New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. |
| Q52715802 | Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens. |
| Q36363261 | Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria |
| Q36335694 | Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? |
| Q34346283 | Pharmacology of polymyxins: new insights into an 'old' class of antibiotics |
| Q33901939 | Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. |
| Q36960059 | Polymyxin B: similarities to and differences from colistin (polymyxin E). |
| Q38953618 | Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis |
| Q93032971 | Polymyxins: To Combine or Not to Combine? |
| Q39293585 | Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria |
| Q91877872 | Prevalence and antibiotic resistance of Acinetobacter baumannii among patients in postcardiac surgery intensive care units of Rajaei Hospital, Tehran |
| Q92302901 | Rational Combinations of Polymyxins with Other Antibiotics |
| Q35541277 | Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing |
| Q42546144 | Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug |
| Q37036489 | Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model |
| Q35598403 | Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model |
| Q38126768 | Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems |
| Q30371239 | The growing burden of antimicrobial resistance. |
| Q91451154 | The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification |
| Q35139454 | The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. |
| Q35432662 | The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model |
| Q35592264 | The use of intravenous colistin among children in the United States: results from a multicenter, case series |
| Q37132130 | Transcriptomic Analysis of the Activity of a Novel Polymyxin against Staphylococcus aureus |
| Q37704397 | Treatment of Acinetobacter infections |
| Q83025534 | [Bacterial death and heteroresistance to antimicrobial agents] |
| Q85001083 | [Colimycin: an old antibiotic which has to be learnt to know] |
| Q34060378 | fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. |
Search more.